百诚医药：8月4日召开董事会会议

Group 1 - The core point of the article is that Baicheng Pharmaceutical announced a board meeting to discuss the use of excess raised funds for permanent working capital supplementation [1] - For the fiscal year 2024, Baicheng Pharmaceutical's revenue composition is as follows: 90.22% from CRO business, 5.2% from CDMO business, and 4.58% from commercial production [1] - As of the report date, Baicheng Pharmaceutical has a market capitalization of 6.5 billion yuan [1] Group 2 - A warning from a German executive in China highlights the dangers of free autonomous driving services, stating it could lead to a disaster for the entire industry [1]